
Global Deferiprone Market By Formulation (Tablet, Oral Solution, Capsule), By Indication (Transfusional Iron Overload, NTDT Caused Iron Overload) and By Region and Country – Global Forecast to 2030
-
17321
-
Jan 2021
-
70
-
PDF
-
-
Request for Sample
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
-
Marketresearch.Biz announces publication of its most recently generated research report titled, “Global Deferiprone Market by Formulation (Tablet, Oral Solution, Capsule), By Indication (Transfusional Iron Overload and NTDT Caused Iron Overload), and by Region and Country – Global Forecast to 2030”, which offers a holistic view of the global deferiprone market through systematic segmentation that covers every aspect of the target market.
The Global Deferiprone Market is projected to be US$ 35.2 Mn in 2020 to reach US$ 37.8 Mn by 2028 at a CAGR of 0.9%.
Deferiprone is an iron chelator specified for the treatment of patients with transfusional iron overload caused owing to thalassemia syndromes, mainly when the current chelation therapy is insufficient. Chelation therapy is utilized to remove the build-up of toxic metals from the body, such as lead, iron, mercury, and arsenic. It prevents patients from getting severe thalassemia symptoms.
Deferiprone, an FDA permitted drug, is majorly utilized to treat transfusion-dependent thalassemia and other related disorders. Deferiprone is a bidentate hydroxypyridone, which has a small molecular weight (139). It forms a stable complex with iron that is then excreted in the urine. It is metabolized by glucuronidation in the liver and has a relatively short half-life of 47-134 minutes, necessitating multiple daily dosing. Deferiprone fallouts in a more substantial reduction in iron levels in those with a difficult iron burden. It might not be as helpful for those with less extensive iron overload. However, this problem can be controlled by increasing Deferiprone's amount administered from 75 to 100 mg/kg/day.
Report Coverage and Deliverables
PDF report and online dashboard will help you understand:- Competitive benchmarking
- Market forecasts
- Company market shares
- Market opportunities
- Latest trends & dynamics
Global Deferiprone Market Revenue (US$ Mn), 2020–2030
Global deferiprone market is segmented based on formulation, indiaction and region/country. Based on formulation, the market is segmented into tablet, oral solution, and capsule. The oral solution is expected to register the highest CAGR, while the tаblеt ѕеgmеnt ассоuntѕ fоr thе mајоrіtу ѕhаrе іn thе glоbаl dеfеrірrоnе mаrkеt. Based on indiaction, the market is segmented into transfusional iron overload and NTDT caused iron overload. The transfusional iron overload segment in the global deferiprone market is estimated to account for a majority revenue share in 2020 end.
Global Deferiprone Market Attractiveness Analysis by Form, 2014–2030
Increasing prevalence of life-threatening diseases such as thalassemia among the population is anticipated to bolster the growth of the global deferiprone market. Thalassemia affects approximately 4.4 of every 10,000 live births globally, thus growing incidence and prevalence of the disease is estimated to drive consumption of deferiprone.
Rising healthcare spending, predominantly in emerging economies, is also estimated to indirectly affect the market growth of deferiprone. Furthermore, development and focus towards the provision and access to the populace in developing countries is expected to have an optimistic impact on the global deferiprone market
The high cost of branded drugs, as compared to its generic counterparts, is also expected to restrain the growth of the market to a certain extent.
The research report on the Global Deferiprone market includes profiles of some of the major companies such as Cipla Limited., Apotex Inc., Swedish Orphan Biovitrum AB (publ)., Genepharm S.A., Lipomed AG., Drug International Limited., Ambrosia Remedies (P) Ltd., and Focus Pharmaceuticals Limited.
Segmentation of the Global Deferiprone Market:
Segmentation by Formulation:
- Tablet
- Oral Solution
- Capsule
Segmentation by Indication:
- Transfusional Iron Overload
- NTDT Caused Iron Overload
Segmentation by Regions:
- North America
- Europe
- APAC
- South America
- MEA
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn -
- Cipla Limited.
- Apotex Inc.
- Swedish Orphan Biovitrum AB (publ).
- Genepharm S.A.
- Lipomed AG.
- Drug International Limited.
- Ambrosia Remedies (P) Ltd.
- Focus Pharmaceuticals Limited.
-
- Chapter 1 Global Deferiprone Market Overview
- 1.1 Introduction
- 1.2 Drivers for Deferiprone Market
- 1.3 Restraints for Deferiprone Market
- 1.4 Opportunities for Deferiprone Market
- 1.5 Global Deferiprone Market by Formulation
- 1.5.1 Global Deferiprone Revenue Comparison by Formulation (2012-2028)
- 1.5.2 Global Deferiprone Revenue Market Share by Formulation in 2018
- 1.5.3 Global Deferiprone Market Attractiveness Analysis by Formulation, 2012-2018
- 1.6 Global Deferiprone Market by Indication
- 1.6.1 Global Deferiprone Revenue Comparison by Indication (2012-2028)
- 1.6.2 Global Deferiprone Revenue Market Share by Indication in 2018
- 1.6.3 Global Deferiprone Market Attractiveness Analysis by Indication, 2012-2018
- 1.7 Global Deferiprone Market Outlook by Region
- 1.7.1 Global Deferiprone Revenue Comparison by Region (2012-2028)
- 1.7.2 Global Deferiprone Revenue Market Share by Region in 2018
- 1.7.3 Global Deferiprone Market Attractiveness Analysis by Region, 2012-2018
- 1.8 Global Deferiprone Market Outlook (2012-2028)
- 1.8.1 Global Deferiprone Revenue (2012-2019)
- 1.8.2 Global Deferiprone Revenue (2020-2028)
- Chapter 2 Global Deferiprone Market Insights
- 2.1 Regulations for Deferiprone Market
- 2.2 PEST Analysis
- 2.3 PORTER's Five Force Analysis
- 2.4 Pricing Analysis by Product Type, 2018
- 2.5 Opportunity Map Analysis
- 2.6 Market Investment Feasibility Analysis
- 2.7 Opportunity Orbits
- 2.8 Industry Chain Analysis
- Chapter 3 Global Deferiprone Revenue by Regions
- 3.1 Global Deferiprone Revenue Comparison by Region (2012-2019)
- 3.2 Global Deferiprone Revenue Comparison by Region (2020-2028)
- Chapter 4 Global Deferiprone Revenue by Formulation
- 4.1 Global Deferiprone Revenue Comparison by Formulation (2012-2019)
- 4.2 Global Deferiprone Revenue Comparison by Formulation (2020-2028)
- Chapter 5 Global Deferiprone Revenue by Indication
- 5.1 Global Deferiprone Revenue Comparison by Indication (2012-2019)
- 5.2 Global Deferiprone Revenue Comparison by Indication (2020-2028)
- Chapter 6 Global Deferiprone Y-o-Y Growth Rate Comparison 2013-2028
- 6.1 Global Deferiprone Y-o-Y Growth Rate by Region
- 6.2 Global Deferiprone Market Y-o-Y Growth Rate by Formulation
- 6.3 Global Deferiprone Y-o-Y Growth Rate by Indication
- Chapter 7 Global Deferiprone Share Comparison 2013-2028
- 7.1 Global Deferiprone Share by Region
- 7.2 Global Deferiprone Market Share by Formulation
- 7.3 Global Deferiprone Share by Indication
- Chapter 8 Global Deferiprone Manufacturer Profiles
- 8.1 Market Competition Scenario Analysis by Manufacturers/Supplier
- 8.2 Company Profiles
- 8.2.1 Cipla Limited.
- 8.2.1.1 Company Overview
- 8.2.1.2 Business Description
- 8.2.1.3 Product Portfolio
- 8.2.1.4 Key Financials
- 8.2.1.5 Key Developments
- 8.2.1.6 SWOT Analysis
- 8.2.2 Apotex Inc.
- 8.2.2.1 Company Overview
- 8.2.2.2 Business Description
- 8.2.2.3 Product Portfolio
- 8.2.2.4 Key Developments
- 8.2.2.5 SWOT Analysis
- 8.2.3 Swedish Orphan Biovitrum AB (publ).
- 8.2.3.1 Company Overview
- 8.2.3.2 Business Description
- 8.2.3.3 Product Portfolio
- 8.2.3.4 Key Financials
- 8.2.3.5 Key Developments
- 8.2.4 Genepharm S.A.
- 8.2.4.1 Company Overview
- 8.2.4.2 Business Description
- 8.2.4.3 Product Portfolio
- 8.2.5 Lipomed AG.
- 8.2.5.1 Company Overview
- 8.2.5.2 Business Description
- 8.2.5.3 Product Portfolio
- 8.2.6 Drug International Limited
- 8.2.6.1 Company Overview
- 8.2.6.2 Business Description
- 8.2.6.3 Product Portfolio
- 8.2.7 Ambrosia Remedies (P) Ltd.
- 8.2.7.1 Company Overview
- 8.2.7.2 Business Description
- 8.2.7.3 Product Portfolio
- 8.2.8 Focus Pharmaceuticals Limited
- 8.2.8.1 Company Overview
- 8.2.8.2 Business Description
- 8.2.8.3 Product Portfolio
- 8.2.1 Cipla Limited.
- Chapter 9 Methodology and Data Source
- 9.1 Methodology/Research Approach
- 9.1.1 Market Size Estimation
- 9.2 Market Breakdown and Data Triangulation
- 9.3 Data Source
- 9.3.1 Secondary Sources
- 9.3.2 Primary Sources
- 9.4 Disclaimer
- 9.1 Methodology/Research Approach
- Chapter 1 Global Deferiprone Market Overview
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!